Natural Compounds: DNA Methyltransferase Inhibitors in Oral Squamous Cell Carcinoma

Applied Biochemistry and Biotechnology

Volumn 177, Issue 3, 2015, Pages 577-594

  Jha, Meenakshi ^a   Aggarwal, Ruchi ^b   Jha, Abhimanyu Kumar ^b   Shrivastava, Anju ^a  

^a UNIVERSITY OF DELHI   (India)

^b IMS ENGINEERING COLLEGE   (India)

Author keywords

Epigenetics; Hypermethylation; Natural compounds; Oral squamous cell carcinoma; Tumor suppressor genes

Indexed keywords

TUMORS;

EPIGENETICS; HYPERMETHYLATION; NATURAL COMPOUNDS; ORAL SQUAMOUS CELL CARCINOMATA; TUMOR SUPPRESSOR GENES;

GENES;

DNA METHYLTRANSFERASE INHIBITOR; NATURAL PRODUCT; ANTINEOPLASTIC AGENT; BIOLOGICAL PRODUCT; DNA (CYTOSINE 5) METHYLTRANSFERASE; ENZYME INHIBITOR;

CARCINOGENESIS; CARCINOMA; DNA METHYLATION; DRUG SCREENING; HUMAN; INDIA; MOUTH SQUAMOUS CELL CARCINOMA; NONHUMAN; REVIEW; TUMOR SUPPRESSOR GENE; ANIMAL; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; ENZYMOLOGY; GENETICS; MOUTH NEOPLASMS;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL PRODUCTS; CARCINOMA, SQUAMOUS CELL; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; ENZYME INHIBITORS; HUMANS; MOUTH NEOPLASMS;

EID: 84942550446     PISSN: 02732289     EISSN: 15590291     Source Type: Journal    
DOI: 10.1007/s12010-015-1768-y     Document Type: Review

References (126)

1. Stewart, B. W., Greim, H., Shuker, D., & Kauppinen, T. (2003). Defence of IARC monographs. Lancet, 361, 13003–13006.
2. Howlader, N., Noone, A. M., Krapcho, M., et al. (Eds.). (2011). SEER Cancer Statistics Review, 1975–2008. Bethesda: National Cancer Institute, 2011. Also available online. Last accessed 06 Feb 2015.
3. Gillison, M. L., D’Souza, G., Westra, W., Sugar, E., Xiao, W., Begum, S., & Viscidi, R. (2008). Distinct risk factor profiles for human papillomavirus type 16-positive and human papillomavirus type 16- negative head and neck cancers. J Natl Cancer Inst, 100, 407–420.
4. Chaturvedi, A. K., Engels, E. A., Anderson, W. F., & Gillison, M. L. (2008). Incidence trends for human papillomavirus-related and -unrelated oral squamous cell carcinomas in the United States. Journal of Clinical Oncology, 26, 612–619.
5. Lingen, M. W., Pinto, A., Mendes, R. A., Franchini, R., Czerninski, R., Tilakaratne, W. M., Partridge, M., Peterson, D. E., & Woo, S. B. (2011). Genetics/epigenetics of oral premalignancy: current status and future research. Oral Diseases, 17, 7–22.
6. Saintigny, P., Zhang, L., Fan, Y.-H., El-Naggar, A. K., Papadimitrakopoulou, V. A., Feng, L., Lee, J. J., Kim, E. S., Hong, W. K., & Mao, L. (2011). Gene expression profiling predicts the development of oral cancer. Cancer Prevention Research, 4, 218–229.
7. Kyrgidis, A., Tzellos, T. G., & Triaridis, S. (2010). Melanoma: stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications. Journal of Carcinogenesis, 9, 1477–3163.
8. Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004). Epigenetics in human disease and prospects for epigenetic therapy. Nature, 429, 457–463.
9. Feinberg, A. P., Ohlsson, R., & Henikoff, S. (2006). The epigenetic progenitor origin of human cancer. Nature Reviews, 7, 21–33.
10. Jones, P. A., & Baylin, S. B. (2002). The fundamental role of epigenetic events in cancer. Nature Reviews Genetics, 3, 415–428.
11. Board, R. E., Knight, L., Greystoke, A., Blackhall, F. H., Hughes, A., Dive, C., & Ranson, M. (2008). DNA methylation in circulating tumour DNA as a biomarker for cancer. Biomarker Insights, 2, 307–319.
12. Bird, A. (2002). DNA methylation patterns and epigenetic memory. Genes and Development, 16, 6–21.
13. Takai, D., & Jones, P. A. (2002). Comprehensive analysis of CpG islands in human chromosomes 21 and 22. Proceedings of the National Academy of Sciences of the United States of America, 99, 3740–3745.
14. Illingworth, R. S., & Bird, A. P. (2009). CpG islands—“a rough guide”. FEBS Letters, 583, 1713–1720.
15. Wang, Y., & Leung, F. C. (2004). An evaluation of new criteria for CpG islands in the human genome as gene markers. Bioinformatics, 20, 1170–1177.
16. Worm, S., & Guldberg, P. (2002). DNA methylation: an epigenetic pathway to cancer and a promising target for anticancer therapy. Journal of Oral Pathology & Medicine, 31, 443–449.
17. Eden, A., Gaudet, F., Waghmare, A., & Jaenisch, R. (2003). Chromosomal instability and tumors promoted by DNA hypomethylation. Science, 300, 455.
18. Bonazzi, V. F., Irwin, D., & Hayward, N. K. (2009). Identification of candidate tumor suppressor genes inactivated by promoter methylation in melanoma. Genes, Chromosomes and Cancer, 48, 10–21.
19. Feinberg, A. P., Cui, H., & Ohlsson, R. (2002). DNA methylation and genomic imprinting: Insightsfrom cancer into epigenetic mechanisms. Seminars in Cancer Biology, 12, 389–398.
20. Robertson, K. D. (2005). DNA methylation and human disease. Nature Reviews Genetics, 6, 597–610.
21. Martinez, R., Martin-Subero, J. I., Rohde, V., Kirsch, M., Alaminos, M., Fernandez, A. F., Ropero, S., Schackert, G., & Esteller, M. (2009). A microarray-based DNA methylation study of glioblastomamultiforme. Epigenetics, 4, 255–264.
22. Piyathilake, C. J., Bell, W. C., Jones, J., et al. (2005). Pattern of nonspecific (or global) DNA methylation in oral carcinogenesis. Head & Neck, 27, 1061–1067.
23. Guerrero-Preston, R., Baez, A., Blanco, A., Berdasco, M., Fraga, M., & Esteller, M. (2009). Global DNA methylation: a common early event in oral cancer cases with exposure to environmental carcinogens or viral agents. Puerto Rico Health Sciences Journal, 28, 24–29.
24. Baba, S., Yamada, Y., Hatano, Y., et al. (2009). Global DNA hypomethylation suppresses squamous carcinogenesis in the tongue and esophagus. Cancer Science, 100, 1186–1191.
25. Gasche, J. A., Hoffmann, J., Boland, C. R., & Goel, A. (2011). Interleukin-6 promotes tumorigenesisby altering DNA methylation in oral cancer cells. International Journal of Cancer, 129, 1053–1063.
26. Supic, G., Kozomara, R., Jovic, N., Zeljic, K., & Magic, Z. (2011). Prognostic significance of tumor- related genes hypermethylation detected in cancer-free surgical margins of oral squamous cell carcinomas. Oral Oncology, 47, 702–708.
27. Diez-Perez, R., Campo-Trapero, J., Cano-Sanchez, J., Lopez-Duran, M., Gonzalez-Moles, M. A., Bascones-Ilundain, J., & Bascones-Martinez, A. (2011). Methylation in oral cancer and pre-cancerous lesions (Review). Oncology Reports, 25, 1203–1209.
28. Towle, R., & Garnis, C. (2012). Methylation-mediated molecular dysregulation in clinical oral malignancy. Journal of Oncology, 2012, 1–12.
29. Mascolo, M., Siano, M., Ilardi, G., Russo, D., Merolla, F., Rosa, G. D., & Staibano, S. (2012). Epigenetic disregulation in oral cancer. International Journal of Molecular Sciences, 13, 2331–2353.
30. Gasche, J. A., & Goel, A. (2012). Epigenetic mechanisms in oral carcinogenesis. Future Oncology, 8, 1407–1425.
31. Huang, M. J., Yeh, K. T., Shih, H. C., Wang, Y. F., Lin, T. H., Chang, J. Y., Shih, M. C., & Chang, J. G. (2002). The correlation between CpG methylation and protein expression of P16 in oral squamous cell carcinomas. International Journal of Molecular Medicine, 10, 551–554.
32. Liu, H. W., Hu, B. Q., & Cao, C. F. (2005). The p16 methylation in oral leukoplakia and oral squamous cell carcinoma. Zhonghua Kou Qiang Yi Xue Za Zhi, 40, 94–97.
33. Ogi, K., Toyota, M., Ohe-Toyota, M., Tanaka, N., Noguchi, M., Sonoda, T., Kohama, G., & Tokino, T. (2002). Aberrant methylation of multiple genes and clinicopathological features in oral squamous cell carcinoma. Clinical Cancer Research, 8, 3164–3171.
34. Viswanathan, M., Tsuchida, N., & Shanmugam, G. (2003). Promoter hypermethylation profile of Tumor associated genes p16, p15, hMLH1, MGMT and E-cadherin in oral squamous cell carcinoma. International Journal of Cancer, 105, 41–46.
35. Kulkarni, V., & Saranath, D. (2004). Concurrent hypermethylation of multiple regulatory genes in chewing tobacco associated oral squamous cell carcinomas and adjacent normal tissues. Oral Oncology, 40, 145–153.
36. Kato, K., Hara, A., Kuno, T., Mori, H., Yamashita, T., Toida, M., & Shibata, T. (2006). Aberrant promoter hypermethylation of p16 and MGMT genes in oral squamous cell carcinomas and the surrounding normal mucosa. Journal of Cancer Research and Clinical Oncology, 132, 735–743.
37. Viet, C. T., Jordan, R. C., & Schmidt, B. L. (2007). DNA promoter hypermethylation in saliva for the early diagnosis of oral cancer. Journal of the California Dental Association, 35, 844–849.
38. Kurasawa, Y., Shiiba, M., Nakamura, M., et al. (2008). PTEN expression and methylation status inoral squamous cell carcinoma. Oncology Reports, 19, 1429–1434.
39. Caamano, J., Zhang, S. Y., Rosvold, E. A., Bauer, B., & Klein-Szanto, A. J. (1993). p53 alterations in human squamous cell carcinomas and carcinoma cell lines. The American Journal of Pathology, 142, 1131–1139.
40. Baral, R., Patnaik, S., & Das, B. R. (1998). Co-overexpression of p53 and c-myc proteins linked with advanced stages of betel- and tobacco-related oral squamous cell carcinomas from eastern India. European Journal of Oral Sciences, 106, 907–913.
41. Roth, M. J., Abnet, C. C., Hu, N., Wang, Q. H., Wie, W. Q., Green, L., D’Alelio, M., Qiao, Y. L., Dawsey, S. M., Taylor, P. R., & Woodson, K. (2006). p16, MGMT, RARbeta2, CLDN3, CRBP and MT1G gene methylation in esophageal squamous cell carcinoma and its precursor lesions. Oncology Reports, 15, 1591–1597.
42. Sawhney, M., Rohatgi, N., Kaur, J., Gupta, S. D., Deo, S. V., Shukla, N. K., & Ralhan, R. (2007). MGMT expression in oral precancerous and cancerous lesions: correlation with progression, nodal metastasis and poor prognosis. Oral Oncology, 43, 515–522.
43. Ishida, E., Nakamura, M., Ikuta, M., et al. (2005). Promotorhypermethylation of p14ARF is a keyalteration for progression of oral squamous cell carcinoma. Oral Oncology, 41, 614–622.
44. Sailasree, R., Abhilash, A., Sathyan, K. M., Nalinakumari, K. R., Thomas, S., & Kannan, S. (2008). Differential roles of p16INK4A and p14ARF genes in prognosis of oral carcinoma. Cancer Epidemiology, Biomarkers and Prevention, 17, 414–420.
45. Yeh, K. T., Chang, J. G., Lin, T. H., et al. (2003). Epigenetic changes of tumor suppressor genes, P15, P16, VHL and P53 in oral cancer. Oncology Reports, 10, 659–663.
46. Hasegawa, M., Nelson, H. H., Peters, E., Ringstrom, E., Posner, M., & Kelsey, K. T. (2002). Patterns of gene promoter methylation in squamous cell cancer of the head and neck. Oncogene, 21, 4231–4236.
47. Shaw, R. J., Liloglou, T., Rogers, S. N., et al. (2006). Promoter methylation of P16, RARβ, E-cadherin, cyclin A1 and cytoglobin in oral cancer: quantitative evaluation using pyrosequencing. British Journal of Cancer, 94, 561–568.
48. Huang, K. H., Huang, S. F., Chen, I. H., Liao, C. T., Wang, H. M., & Hsieh, L. L. (2009). Methylationof RASSF1A, RASSF2A, and HIN-1 is associated with poor outcome after radiotherapy, but not surgery, in oral squamous cell carcinoma. Clinical Cancer Research, 15, 4174–4180.
49. Uesugi, H., Uzawa, K., Kawasaki, K., et al. (2005). Status of reduced expression and hypermethylation of the APC tumor suppressor gene in human oral squamous cell carcinoma. International Journal of Molecular Medicine, 15, 597–602.
50. Gao, S., Eiberg, H., Krogdahl, A., Liu, C. J., & Sorensen, J. A. (2005). Cytoplasmic expression of E-cadherin and β- Catenin correlated with LOH and hypermethylation of the APC gene in oral squamous cell carcinomas. Journal of Oral Pathology & Medicine, 34, 116–119.
51. Gonzalez-Ramirez, I., Ramirez-Amador, V., Irigoyen-Camacho, M. E., et al. (2011). hMLH1 promoter methylation is an early event in oral cancer. Oral Oncology, 47, 22–26.
52. Gao, F., Huang, C., Lin, M., et al. (2009). Frecuent inactivation of RUNX3 by promoter hypermethylation and protein mislocation in oral squamous cell carcinomas. Journal of Cancer Research and Clinical Oncology, 135, 739–747.
53. Sogabe, Y., Suzuki, H., Toyota, M., Ogi, K., Imai, T., Nojima, M., Sasaki, Y., Hiratsuka, H., & Tokino, T. (2008). Epigenetic inactivation of SFRP genes in oral squamous cell carcinoma. International Journal of Oncology, 32, 1253–1261.
54. Suzuki, E., Imoto, I., Pimkhaokham, A., et al. (2007). PRTFDC1, a possible tumor-suppressor gene, is frequently silenced in oral squamous-cell carcinomas by aberrant promoter hypermethylation. Oncogene, 26, 7921–7932.
55. Suzuki, M., Shinohara, F., Nishimura, K., Echigo, S., & Rikiishi, H. (2007). Epigenetic regulation ofchemosensitivity to 5-fluorouracil and cisplatin by zebularine in oral squamous cell carcinoma. International Journal of Oncology, 31, 1449–1456.
56. Suzuki, M., Shinohara, F., Endo, M., Sugazaki, M., Echigo, S., & Rikiishi, H. (2008). Zebularine suppresses the apoptotic potential of 5-fluorouracil via cAMP/PKA/CREB pathway against human oral squamous cell carcinoma cells. Cancer Chemotherapy and Pharmacology, 64, 223–232.
57. Murakami, J., Lee, Y. J., Kokeguchi, S., et al. (2007). Depletion of O6-methylguanine-DNA methyltransferase by O6-benzylguanine enhances 5-FU cytotoxicity in colon and oral cancer cell lines. Oncology Reports, 17, 1461–1467.
58. Timmermann, S., Hinds, P. W., & Munger, K. (1998). Re-expression of endogenous p16ink4a inOral squamous cell carcinoma lines by 5-aza-2'-deoxycytidine treatment induces a senescence-like state. Oncogene, 17, 3445–3453.
59. Szyf, M., Pakneshan, P., & Rabbani, S. A. (2004). DNA demethylation and cancer: therapeutic implications. Cancer Letters, 211, 133–143.
60. min/+ mice by (-)-epigallocatechin-3-gallate, the major catechin in green tea. Cancer Research, 65, 10623–10631.
61. Wilson, A. S., Power, B. E., & Molly, P. L. (2007). DNA hypomethylation and human diseases. Biochimica et Biophysica Acta, 1775, 138–162.
62. Tsao, A. S., Liu, D., Martin, J., et al. (2009). Phase II randomized, placebo-controlled trial of greentea extract in patients with high-risk oral premalignant lesions. Cancer Prevention Research (Philadelphia, Pa.), 2, 931–941.
63. Ide, R., Fujino, Y., Hoshiyama, Y., Mizoue, T., Kubo, T., Pham, T. M., Shirane, K., Tokui, N., Sakata, K., Tamakoshi, A., et al. (2007). A prospective study of green tea consumption and oral cancer incidence in Japan. Annals of Epidemiology, 17, 821–826.
64. Radoi, L., Paget-Bailly, S., Menvielle, G., Cyr, D., Schmaus, A., Carton, M., Guida, F., Cenee, S., Sanchez, M., Guizard, A. V., et al. (2013). Tea and coffee consumption and risk of oral cavity cancer: results of a large population-based case-control study, the ICARE study. Cancer Epidemiology, 37, 284–289.
65. Li, N., Han, C., & Chen, J. (1999). Tea preparations protect against DMBA-induced oral carcinogenesis in hamsters. Nutrition and Cancer, 35, 73–79.
66. Sugimura, T. (1992). Multistep carcinogenesis: a 1992 perspective. Science, 258, 603–607.
67. Srinivasan, P., Suchalatha, S., Babu, P. V., et al. (2008). Chemopreventive and therapeutic modulation of green tea polyphenols on drug metabolizing enzymes in 4-Nitroquinoline 1-oxideinduced oral cancer. Chemico-Biological Interactions, 172, 224–234.
68. Chang, H. C., Cho, C. Y., & Hung, W. C. (2007). Downregulation of RECK by promoter methylation correlates with lymph node metastasis in non-small cell lung cancer. Cancer Science, 98, 169–173.
69. Cho, C. Y., Wang, J. H., Chang, H. C., et al. (2007). Epigenetic inactivation of the metastasis suppressor RECK enhances invasion of human colon cancer cells. Journal of Cellular Physiology, 213, 65–69.
70. Kato, K., Long, N. K., Makita, H., et al. (2008). Effects of green tea polyphenol on methylation status of RECK gene and cancer cell invasion in oral squamous cell carcinoma cells. British Journal of Cancer, 99, 647–654.
71. Fang, M. Z., Wang, Y. W., Ai, N., Hou, Z., Sun, Y., Lu, H., Welsh, W., & Yang, C. S. (2003). Tea polyphenol (−)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Research, 63, 7563–7570.
72. Khafif, S. P., Schantz, M., et al. (1998). Green tea regulates cell cycle progression in oral Leukoplakia. Head & Neck, 20, 528–534.
73. Masuda, M., Suzui, M., & Weinstein, I. B. (2001). Effects of epigallocatechin-3-gallate on growth, epidermal growth factor receptor signaling pathways, gene expression, and chemosensitivity in human head and neck squamous cell carcinoma cell lines. Clinical Cancer Research, 7, 4220–4229.
74. Liu, X., Zhang, D. Y., Zhang, W., et al. (2011). The effect of green tea extract and EGCG on the Signaling network in squamous cell carcinoma. Nutrition and Cancer, 63, 466–475.
75. Hsu, S., Lewis, J., Singh, B., et al. (2003). Green tea polyphenol targets the mitochondria in tumorcells inducing caspase 3- dependent apoptosis. Anticancer Research, 23, 1533–1539.
76. Hsu, S., Farrey, K., Wataha, J., et al. (2005). Role of p21WAF1 in green tea polyphenol-induced growth arrest and apoptosis of oral carcinoma cells. Anticancer Research, 25, 63–67.
77. Lee, W. J., Shim, J. Y., & Zhu, B. T. (2005). Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Molecular Pharmacology, 68, 1018–1030.
78. Lee, W. J., & Zhu, B. T. (2006). Inhibition of DNA methylation by caffeic acid and chlorogenicacid, two common catechol-containing coffee polyphenols. Carcinogenesis, 27, 269–277.
79. Fang, M., Chen, D., & Yang, C. S. (2007). Dietary polyphenols may affect DNA methylation. The Journal of Nutrition, 137, 223S–228S.
80. Fang, M. Z., Chen, D., Sun, Y., Jin, Z., Christman, J. K., & Yang, C. S. (2005). Reversal of hypermethylation and reactivation of p16INK4a, RAR-β, and MGMT genes by genistein and other isoflavones from soy. Clinical Cancer Research, 11, 7033–7041.
81. Yang, Y., Zhou, Z. T., & Ge, J. P. (2006). Effect of genistein on DMBA-induced oral carcinogenesis in hamster. Carcinogenesis, 27, 578–583.
82. Myoung, H., Hong, S. P., Yun, P. Y., Lee, J. H., & Kim, M. J. (2003). Anticancer effect of genistein in oral squamous cell carcinoma with respect to angiogenesis and in vitro invasion. Cancer Science, 94, 215–220.
83. Graf, B. A., Milbury, P. E., & Blumberg, J. B. (2005). Flavonols, flavonones, flavanones and human health: epidemological evidence. Journal of Medicinal Food, 8, 281–290.
84. Arts, I. C. W., & Hollman, P. C. H. (2005). Polyphenols and disease risk in epidemiologic studies. The American Journal of Clinical Nutrition, 81, 317–325.
85. Hauser, A. T., & Jung, M. (2008). Targeting epigenetic mechanisms: potential of natural products in cancer chemoprevention. Planta Medica, 74, 1593–1601.
86. Gilbert, E. R., & Liu, D. (2010). Flavonoids influence epigenetic-modifying enzyme activity: structure–function relationships and the therapeutic potential for cancer. Current Medicinal Chemistry, 17, 1756–1768.
87. Li, Y., & Tollefsbol, T. O. (2010). Impact on DNA methylation in cancer prevention and therapy by bioactive dietary components. Current Medicinal Chemistry, 17, 2141–2151.
88. Tan, S., Wang, C., Lu, C., Zhao, B., Cui, Y., Shi, X., & Ma, X. (2009). Quercetin is able to demethylate the p16INK4a gene promoter. Chemotherapy, 55, 6–10.
89. Fini, L., Selgrad, M., Fogliano, V., et al. (2007). Annurca apple polyphenols have potent demethylating activity and can reactivate silenced tumor suppressor genes in colorectal cancer cells. The Journal of Nutrition, 137, 2622–2628.
90. Agarwal, S., Karishma, S. A., Jagadeesh, S., et al. (2007). Mahanine reverses an epigenetically silenced tumor suppressor gene RASSF1A in human prostate cancer cells. Biochemical and Biophysical Research Communications, 362, 212–217.
91. Liu, Z., Xie, Z., Jones, W., Pavlovicz, R. E., Liu, S., Yu, J., et al. (2009). Curcumin is a potent DNA hypomethylation agent. Bioorganic and Medicinal Chemistry Letters, 19, 706–709.
92. Jha, A. K., Nikbakht, M., Parashar, G., Shrivastava, A., Capalash, N., & Kaur, J. (2010). Reversal of hypermethylation and reactivation of the RARbeta2 gene by natural compounds in cervical cancer cell lines. Folia Biologica (Praha), 56, 195–200.
93. Liu, Y. L., Yang, H. P., Gong, L., Tang, C. L., & Wang, H. J. (2011). Hypomethylation effects of curcumin, demethoxycurcumin and bisdemethoxycurcumin on WIF-1 promoter in non-small cell lung cancer cell lines. Molecular Medicine Reports, 4, 675–679.
94. Khor, T. O., Huang, Y., Wu, T. Y., Shu, L., Lee, J., & Kong, A. N. (2011). Pharmacodynamics of curcumin as DNA hypomethylation agent in restoring the expression of Nrf2 via promoter CpGsdemethylation. Biochemical Pharmacology, 82, 1073–1078.
95. Shu, L., Khor, T. O., Lee, J. H., Boyanapalli, S. S., Huang, Y., Wu, T. Y., et al. (2011). EpigeneticCpGdemethylation of the promoter and reactivation of the expression of Neurog1 by curcumin in prostate LNCaP cells. The AAPS Journal, 13, 606–614.
96. Naveed, A. C., Bhavaniprasad, V., Anbarasu, K., Nadeem, S., & Trupti, N. P. (2013). From natural products to drugs for epimutation computer-aided drug design. Applied Biochemistry and Biotechnology, 170, 164–175.
97. Paluszczak, J., Krajka-Kuzniak, V., & Baer-Dubowska, W. (2010). The effect of dietary polyphenols on the epigenetic regulation of gene expression in MCF7 breast cancer cells. Toxicology Letters, 192, 119–125.
98. Yan, L., Junye, L., Xinpig, L., Kefei, X., Yun, W., Fuyang, L., & Libo, Y. (2006). Resveratrol- induced cell inhibition of growth and apoptosis in MCF7 human breast cancer cells are associated with modulation of phosphorylated akt and caspase-9. Applied Biochemistry and Biotechnology, 135, 181–192.
99. Stefanska, B., Salame, P., Bednarek, A., & Fabianowska-Majewska, K. (2011). Comparative effectsof retinoic acid, vitamin D and resveratrol alone and in combination with adenosine analogues on methylation and expression of phosphatase and tensin homologue tumour suppressor gene in breast cancer cells. The British Journal of Nutrition, 107, 781–790.
100. Papoutsis, A. J., Borg, J. L., Selmin, O. I., & Romagnolo, D. F. (2011). BRCA-1 promoter hypermethylation and silencing induced by the aromatic hydrocarbon receptor-ligand TCDD are prevented by resveratrol in MCF-7 cells. The Journal of Nutritional Biochemistry, 23, 1324–1332.
101. Meeran, S. M., Patel, S. N., & Tollefsbol, T. O. (2010). Sulforaphane causes epigenetic repression of hTERT expression in human breast cancer cell lines. PLoS One, 5, e11457.
102. Wang, L. G., Beklemisheva, A., Liu, X. M., Ferrari, A. C., Feng, J., & Chiao, J. W. (2007). Dual action on promoter demethylation and chromatin by an isothiocyanate restored GSTP1 silenced in prostate cancer. Molecular Carcinogenesis, 46, 24–31.
103. King-Batoon, A., Leszczynska, J. M., & Klein, C. B. (2008). Modulation of gene methylation bygenistein or lycopene in breast cancer cells. Environmental and Molecular Mutagenesis, 49, 36–45.
104. Pina, I. C., Gautschi, J. T., Wang, G. Y., et al. (2003). Psammaplins from the sponge Pseudoceratinapurpurea: inhibition of both histone deacetylase and DNA methyltransferase. The Journal of Organic Chemistry, 68, 3866–3873.
105. McPhail, K. L., France, D., Cornell-Kennon, S., & Gerwick, W. H. (2004). Peyssonenynes A and B, novel enediyneoxylipins with DNA methyl transferase inhibitory activity from the red marine alga Peyssonneliacaulifera. Journal of Natural Products, 67, 1010–1013.
106. Liu, Z., Liu, S., Xie, Z., Pavlovicz, R. E., Wu, J., Chen, P., et al. (2009). Modulation of DNA methylation by a sesquiterpene lactone parthenolide. The Journal of Pharmacology and Experimental Therapeutics, 329, 505–514.
107. Serra, A. T., Matias, A. A., Almeida, A. P., Bronze, M. R., Alves, P. M., de Sousa, H. C., & Duarte, C. M. (2011). Processing cherries (Prunusavium) using supercritical fluid technology. Part 2: evaluation of SCF extracts as promising natural chemotherapeutical agents. Journal of Supercritical Fluids, 55, 1007–1013.
108. James, T., & Belanger, N. D. (1998). Perillyl alcohol: applications in oncology. Alternative Medicine Review, 3, 448–457.
109. Jaganathan, S. K., & Supriyanto, E. (2012). Antiproliferative and molecular mechanism of eugenol-induced apoptosis in cancer cells. Molecules, 17, 6290–6304.
110. Kang, J. Y., Lee, J. M., Chun, K. S., et al. (1998). Induction of apoptosis in HL-60 cells and inhibition of mouse skin tumor promotion by diarylheptanoids from Alpiniaoxyphylla Miquel (Zingiberaceae). Proceedings of the American Association for Cancer Research, 39, 641.
111. Chinery, R., Beauchamp, R. D., Shyr, Y., Kirkland, S. C., Coffcy, R. J., & Morrow, J. D. (1998). Antioxidants reduce cyclooxygenase- 2 expression, prostaglandin production, and prolioferation in colorectal- cancer cells. Cancer Research, 58, 2323–2327.
112. Chun, K. S., Sohn, Y., Kim, H. S., et al. (1999). Antitumour promoting potential of naturally occurring diaryheptenoids structurally related to curcumin. Mutation Research, 428, 49–57.
113. Kim, J. Y., Kim, E. H., Kim, S. U., Kwon, T. K., & Choi, K. S. (2010). Capsaicin sensitizes malignantglioma cells to TRAILmediated apoptosis via DR5 upregulation and surviving downregulation. Carcinogenesis, 31, 367–375.
114. Wolvetang, E. J., Larm, J. A., Moutsoulas, P., & Lawen, A. (1996). Apoptosis induced by inhibitors of the plasma membrane NADH- oxidase involves Bcl-2 and calcineurin. Cell Growth and Differentiation, 7, 1315–1325.
115. Surh, Y.-J., Lee, E., & Lee, J. M. (1998). Chemoprotective properties of some pungent ingredients present in red pepper and ginger. Mutation Research, 402, 259–267.
116. Shukla, Y., & Singh, M. Cancer preventive properties of ginger: a brief review. Food and Chemical Toxicology, 45, 683–690.
117. Lee, E., & Surh, Y.-J. (1998). Induction of apoptosis in HL-60 cells by pungent vanilloids,[6]-gingerol and [6]-paradol. Cancer Letters, 134, 163–168.
118. Flynn, D. L., Rafferty, M. F., & Boctor, A. M. (1986). Inhibition of human neutrophil 5-lipoxygenaseactivity by gingerdione, shogaol, capsaicin and related pungent compounds. Prostaglandins, Leukotrienes, and Medicine, 24, 195–198.
119. Kiuchi, F., Iwakami, S., Shibuya, M., Hanaoka, F., & Sankawa, U. (1992). Inhibition of prostaglandin and leukotriene biosynthesis by gingerols and diarylheptanoids. Chemical and Pharmaceutical Bulletin, 40, 387–391.
120. Samaha, H. S., Kelloff, G. J., Steele, V., Rao, C. V., & Reddy, B. S. (1997). Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon chemoprevention and promotion. Cancer Research, 57, 1301–1305.
121. Nelson, E. K. (1934). The occurrence of pentamethylflavonol in tangerine peel. Journal of the American Chemical Society, 56, 1392–1393.
122. Hirano, T., Abe, K., Gotoh, M., & Oka, K. (1995). Citrus flavone tangeretin inhibits leukaemic HL-60 cell growth partially through induction of apoptosis with less cytotoxicity on normallymphocytes. British Journal of Cancer, 72, 1380–1388.
123. Chobotova, K., Vernallis, A. B., & Majid, F. A. (2010). BromelainÊs activity and potential as an anti-cancer agent: current evidence and perspectives. Cancer Letters, 290, 148–156.
124. Nadzirah, K. Z., Zainal, S., Noriham, A., & Normah, I. (2013). Efficacy of selected purification techniques for bromelain. International Food Research Journal, 20, 43–46.
125. Bhui, K., Tyagi, S., Prakash, B., & Shukla, Y. (2010). Pineapple bromelain induces autophagy, facilitating apoptotic response in mammary carcinoma cells. Biofactors, 36, 474–482.
126. Pillai, K., Akhter, J., Chua, T. C., & Morris, D. L. (2013). Anticancer property of bromelain with therapeutic potential in malignant peritoneal mesothelioma. Cancer Investigation, 31, 241–250.